Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 775 of 1475 entries
View as:

Effectiveness of KOS-862 in the Treatment of Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00080509 Org: User:
Start: 12/31/03 End: 11/30/04 Due: 11/30/05

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04550195 Org: User:
Start: 09/17/20 End: 03/03/21 Due: 03/03/22

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00798252 Org: User:
Start: 03/31/09 End: 05/31/15 Due: 05/31/16

Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

Phase: N/A Priority: Normal
NCT ID: NCT03161613 Org: User:
Start: 07/17/17 End: 04/01/19 Due: 04/01/20

A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04161911 Org: User:
Start: 10/29/18 End: 11/19/18 Due: 11/19/19

A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

Phase: N/A Priority: Normal
NCT ID: NCT06971185 Org: User:
Start: 11/22/24 End: 08/01/25 Due: 08/01/26

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Phase: N/A Priority: Normal
NCT ID: NCT01515189 Org: User:
Start: 02/17/12 End: 08/17/17 Due: 08/17/18

A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT03804554 Org: User:
Start: 10/03/18 End: 08/12/21 Due: 08/12/22

A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00207025 Org: User:
Start: 10/31/04 End: - Due: -

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Phase: N/A Priority: Normal
NCT ID: NCT01396252 Org: User:
Start: 09/30/11 End: 05/31/12 Due: 05/31/13

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

Phase: N/A Priority: Normal
NCT ID: NCT06421311 Org: User:
Start: 07/30/24 End: 04/04/25 Due: 04/04/26

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05064436 Org: User:
Start: 12/10/21 End: 12/18/23 Due: 12/18/24

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03110107 Org: User:
Start: 05/04/17 End: 04/04/24 Due: 04/04/25

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase: N/A Priority: Normal
NCT ID: NCT02719613 Org: User:
Start: 07/15/16 End: 11/13/25 Due: 11/13/26

A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.

Phase: N/A Priority: Normal
NCT ID: NCT04045639 Org: User:
Start: 06/30/19 End: 01/12/21 Due: 01/12/22

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02327273 Org: User:
Start: 10/31/14 End: 05/31/15 Due: 05/31/16

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

Phase: N/A Priority: Normal
NCT ID: NCT03241264 Org: User:
Start: 08/28/16 End: 10/21/16 Due: 10/21/17

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03417037 Org: User:
Start: 05/24/18 End: 08/20/25 Due: 08/20/26

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03712540 Org: User:
Start: 09/06/18 End: 11/08/18 Due: 11/08/19

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03029780 Org: User:
Start: 02/16/17 End: 06/15/21 Due: 06/15/22

Korean Post-marketing Surveillance for Orencia®

Phase: N/A Priority: Normal
NCT ID: NCT01583244 Org: User:
Start: 03/31/10 End: 02/29/16 Due: 02/28/17

Risk of CV Events With EFV vs. EFV-free Regimens

Phase: N/A Priority: Normal
NCT ID: NCT02426866 Org: User:
Start: 12/31/14 End: 01/31/15 Due: 01/31/16

A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan

Phase: N/A Priority: Normal
NCT ID: NCT06181617 Org: User:
Start: 12/06/23 End: 06/30/25 Due: 06/30/26

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

Phase: N/A Priority: Normal
NCT ID: NCT01708889 Org: User:
Start: 09/30/12 End: 02/28/13 Due: 02/28/14

Subcutaneous Pharmacokinetics of Belatacept

Phase: N/A Priority: Normal
NCT ID: NCT00569803 Org: User:
Start: 12/31/07 End: 08/31/08 Due: 08/31/09